We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
In the latest close session, Zoetis (ZTS - Free Report) was down 1.18% at $81.03. The stock trailed the S&P 500, which registered a daily loss of 0.52%. On the other hand, the Dow registered a loss of 1.24%, and the technology-centric Nasdaq decreased by 0.21%.
Shares of the animal health company have appreciated by 16.69% over the course of the past month, outperforming the Medical sector's gain of 3.23%, and the S&P 500's loss of 1.21%.
The investment community will be closely monitoring the performance of Zoetis in its forthcoming earnings report. The company is scheduled to release its earnings on November 5, 2026. The company's upcoming EPS is projected at $1.51, signifying a 11.18% drop compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.3 billion, indicating a 4.11% decrease compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.14 per share and revenue of $9.24 billion, which would represent changes of -4.21% and -2.39%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Zoetis. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.96% lower within the past month. Zoetis is holding a Zacks Rank of #4 (Sell) right now.
Digging into valuation, Zoetis currently has a Forward P/E ratio of 13.35. This indicates a discount in contrast to its industry's Forward P/E of 16.81.
It is also worth noting that ZTS currently has a PEG ratio of 1.21. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Medical - Drugs industry had an average PEG ratio of 1.9.
The Medical - Drugs industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 92, positioning it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ZTS in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest close session, Zoetis (ZTS - Free Report) was down 1.18% at $81.03. The stock trailed the S&P 500, which registered a daily loss of 0.52%. On the other hand, the Dow registered a loss of 1.24%, and the technology-centric Nasdaq decreased by 0.21%.
Shares of the animal health company have appreciated by 16.69% over the course of the past month, outperforming the Medical sector's gain of 3.23%, and the S&P 500's loss of 1.21%.
The investment community will be closely monitoring the performance of Zoetis in its forthcoming earnings report. The company is scheduled to release its earnings on November 5, 2026. The company's upcoming EPS is projected at $1.51, signifying a 11.18% drop compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $2.3 billion, indicating a 4.11% decrease compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.14 per share and revenue of $9.24 billion, which would represent changes of -4.21% and -2.39%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Zoetis. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.96% lower within the past month. Zoetis is holding a Zacks Rank of #4 (Sell) right now.
Digging into valuation, Zoetis currently has a Forward P/E ratio of 13.35. This indicates a discount in contrast to its industry's Forward P/E of 16.81.
It is also worth noting that ZTS currently has a PEG ratio of 1.21. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Medical - Drugs industry had an average PEG ratio of 1.9.
The Medical - Drugs industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 92, positioning it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ZTS in the coming trading sessions, be sure to utilize Zacks.com.